Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease (NAFLD) — now renamed Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) per 2023 multi-society nomenclature consensus — encompasses a spectrum of liver diseases characterized by hepatic steatosis (>5% hepatocytes containing fat) in the absence of significant alcohol consumption, and associated with at least one cardiometabolic risk factor. It ranges from simple steatosis (MASL) to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with or without fibrosis, and can progress to cirrhosis and hepatocellular carcinoma (HCC).

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Etiology and Risk Factors
5. Clinical Presentation
6. Diagnosis
7. Treatment
8. Complications
9. Prognosis
10. Prevention
11. Recent Research and Advances
12. References

1. Overview

MASLD/NAFLD represents the hepatic manifestation of metabolic syndrome and is now the most prevalent chronic liver disease worldwide. The disease spectrum includes:

• MASL (Metabolic dysfunction-Associated Steatotic Liver): Simple steatosis with cardiometabolic risk factors; minimal risk of progression
• MASH (Metabolic dysfunction-Associated Steatohepatitis): Steatosis + hepatocellular injury (ballooning degeneration) ± lobular inflammation ± fibrosis; risk of progression to cirrhosis
• MASH with advanced fibrosis (F3) or cirrhosis (F4): Significantly increased risk of liver-related mortality and HCC

The 2023 nomenclature change from NAFLD/NASH to MASLD/MASH by the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and allied organizations reflects a shift toward a positive diagnostic framework based on cardiometabolic criteria rather than exclusion of alcohol.

2. Epidemiology

MASLD affects approximately 38% of the global adult population (approximately 2.5 billion people), making it the most common liver disease worldwide. Prevalence in the United States is estimated at 25–30% of adults. MASH affects 3–5% of the global adult population. The prevalence of MASLD has increased by approximately 50% over the past 30 years, parallel to the global rise in obesity and type 2 diabetes.

Prevalence is highest in the Middle East and Latin America (30–40%), followed by Asia (25–30%), the United States (25–30%), and Europe (20–25%). Among individuals with obesity, T2DM, or metabolic syndrome, prevalence of MASLD exceeds 60–80% and MASH 30–40%. Hispanic Americans (particularly of Mexican origin) have the highest MASLD prevalence in the United States due to PNPLA3 genetic variants; Black Americans have lower prevalence despite higher rates of metabolic risk factors, also partly explained by genetic factors.

MASLD is now the most rapidly growing indication for liver transplantation and is projected to become the leading cause of transplant by 2030. Annual incidence of HCC in MASH cirrhosis is 2–4%, compared to 0.3% in MASLD without cirrhosis.

3. Pathophysiology

Multiple Hit Hypothesis

The original "two-hit" hypothesis (steatosis as first hit, oxidative stress and inflammation as second hit) has been superseded by the "multiple parallel hits" model. Multiple simultaneous metabolic insults act on genetically susceptible individuals to promote progression from steatosis to steatohepatitis and fibrosis:

Hepatic Lipid Accumulation

Insulin resistance leads to increased hepatic de novo lipogenesis (DNL) via SREBP-1c activation (carbohydrate excess) and increased flux of free fatty acids (FFAs) from adipose tissue lipolysis to the liver. Impaired VLDL export and reduced beta-oxidation of FFAs compound hepatic lipid accumulation. Ectopic hepatic fat is stored as triglycerides (relatively inert) but generates toxic lipid intermediates: ceramides, diacylglycerols, and lysophosphatidylcholine (lipotoxicity).

Lipotoxicity and Hepatocyte Injury

Saturated fatty acids (palmitate, stearate) activate the unfolded protein response (UPR/ER stress), mitochondrial dysfunction, and oxidative stress. Reactive oxygen species (ROS) from impaired mitochondrial beta-oxidation and CYP2E1-mediated microsomal oxidation cause lipid peroxidation, mitochondrial DNA damage, and activation of c-Jun N-terminal kinase (JNK) — a central mediator of hepatocyte apoptosis in MASH. Lipid-induced apoptosis releases danger signals (DAMPs: HMGB1, extracellular vesicles) activating Kupffer cells and promoting inflammatory cytokine release (TNF-α, IL-1β, IL-6).

Gut-Liver Axis

Intestinal dysbiosis and increased intestinal permeability (leaky gut) allow translocation of bacterial products (LPS, lipoteichoic acid, bile acids) to the portal circulation, activating hepatic toll-like receptors (TLR4, TLR9) on Kupffer cells and HSCs. Altered bile acid metabolism (with increased secondary bile acids and reduced FXR signaling) further contributes to hepatic inflammation and fibrogenesis.

Fibrogenesis

Chronic hepatocyte injury and inflammation activate HSCs via TGF-β1, PDGF, and leptin signaling. Adipokine imbalance (elevated leptin, reduced adiponectin) promotes HSC activation. Progressive fibrosis follows the pattern of perisinusoidal (pericellular) fibrosis in zone 3 (perivenular, centrizonal distribution), in contrast to the portal-based fibrosis of viral hepatitis.

Genetic Determinants

• PNPLA3 (I148M variant, rs738409): Most important genetic variant; found in 30–50% of European, 45% of Hispanic, and 15% of Black Americans; alters lipid droplet remodeling in hepatocytes and HSCs; increases risk of MASLD, MASH, fibrosis, and HCC 3-5 fold per risk allele
• TM6SF2 (E167K variant): Reduces VLDL secretion, promotes hepatic lipid retention; associated with higher fibrosis progression
• MBOAT7: Associated with increased hepatic inflammation and fibrosis
• HSD17B13: Loss-of-function variant (rs72613567) protects against MASH and cirrhosis progression; target for antisense oligonucleotide therapy (ARO-HSD)

4. Etiology and Risk Factors

Primary Metabolic Risk Factors (MASLD Diagnostic Criteria)

MASLD diagnosis requires steatosis plus at least one of the following cardiometabolic criteria:

• BMI ≥25 kg/m² (≥23 kg/m² in Asian populations), or waist circumference >94 cm (male) / >80 cm (female)
• Fasting glucose ≥100 mg/dL, 2h post-load glucose ≥140 mg/dL, HbA1c ≥5.7%, or type 2 diabetes mellitus
• Blood pressure ≥130/85 mmHg or antihypertensive treatment
• Plasma triglycerides ≥150 mg/dL or lipid-lowering treatment
• HDL-C <40 mg/dL (male) or <50 mg/dL (female)

Additional Risk Factors for Progression to MASH and Fibrosis

• Obesity (particularly visceral/central adiposity; BMI >35 kg/m²)
• Type 2 diabetes mellitus (3-4 fold increased risk of advanced fibrosis)
• Metabolic syndrome (3 or more components)
• PNPLA3 risk genotype (I148M); TM6SF2, MBOAT7 variants
• Age >50 years, male sex, postmenopausal status in women
• Hypothyroidism, polycystic ovary syndrome, sleep apnea
• Dietary factors: high fructose (corn syrup) intake, ultra-processed food consumption, low omega-3 fatty acid intake
• Sedentary lifestyle, sarcopenia

5. Clinical Presentation

The majority of MASLD patients (approximately 80%) are asymptomatic and diagnosed incidentally on imaging or elevated liver enzymes detected on routine blood tests. Symptomatic patients may report:

• Fatigue (most common symptom), malaise, reduced exercise tolerance
• Right upper quadrant or epigastric discomfort (hepatic capsule stretch from hepatomegaly)
• Symptoms of metabolic comorbidities: polydipsia/polyuria (diabetes), dyspnea on exertion (heart failure, sleep apnea)

Physical Examination

• Obesity (central/visceral adiposity; increased waist circumference)
• Hepatomegaly: smooth, non-tender liver edge; present in 50–75% of patients with MASLD
• Acanthosis nigricans (insulin resistance marker at nape of neck, axillae)
• Features of metabolic syndrome: hypertension, central obesity
• Signs of advanced disease/cirrhosis: splenomegaly, spider angiomata, caput medusae, jaundice, ascites, asterixis, palmar erythema

Elevated liver enzymes (ALT > AST pattern, typically 1–4 times ULN) are the most common laboratory finding prompting investigation. However, normal ALT does not exclude significant MASH or even advanced fibrosis — approximately 25% of MASH cirrhosis patients have normal ALT.

6. Diagnosis

Initial Evaluation

• Liver enzymes: ALT, AST (AST:ALT ratio <1 in MASLD, >2 suggests ALD); ALP, GGT; bilirubin, albumin, INR (assess synthetic function)
• Metabolic workup: Fasting glucose, HbA1c, fasting lipid panel; BMI and waist circumference
• Exclusion of other liver diseases: Alcohol history (AUDIT score); hepatitis B and C serology; ANA, anti-SMA (autoimmune hepatitis); iron studies/ferritin (hemochromatosis); ceruloplasmin (Wilson's disease in patients <40); thyroid function; celiac serology

Imaging

• Liver ultrasound: First-line; detects steatosis ≥20–30%; increased echogenicity (bright liver), hepatomegaly, posterior beam attenuation; insensitive for mild steatosis and cannot distinguish MASL from MASH or assess fibrosis
• Controlled attenuation parameter (CAP) on FibroScan: Quantifies steatosis (S0 <238 dB/m, S1 238–259, S2 260–291, S3 ≥292); simultaneously measures liver stiffness for fibrosis; point-of-care, non-invasive
• MRI-PDFF (proton density fat fraction): Most accurate non-invasive method for hepatic steatosis quantification; sensitive for steatosis ≥5%; useful for clinical trials and monitoring treatment response
• MR elastography: Most accurate non-invasive fibrosis assessment; superior to transient elastography in obese patients and those with ascites; AUROC 0.93 for cirrhosis

Non-Invasive Fibrosis Markers

• FIB-4 index: [Age × AST] / [Platelets × √ALT]; <1.30 excludes advanced fibrosis (≥F3) with high NPV; >2.67 predicts advanced fibrosis; indeterminate 1.30–2.67 requires further evaluation; 2024 EASL/AASLD guidelines use FIB-4 as initial risk stratification
• NAFLD Fibrosis Score (NFS): Uses age, BMI, AST/ALT, albumin, platelets, hyperglycemia; similar performance to FIB-4
• Enhanced Liver Fibrosis (ELF) test: Serum matrix markers (HA, PIIINP, TIMP-1); FDA-approved for fibrosis staging in MASLD; AUROC 0.87 for advanced fibrosis
• Transient elastography (FibroScan): LSM >8 kPa suggests significant fibrosis in MASLD; >12 kPa suggests cirrhosis; affected by steatosis, food intake, inflammation; BMI >40 reduces reliability (use XL probe)

Liver Biopsy

Still required to definitively diagnose MASH and stage fibrosis. Graded by the NASH Clinical Research Network (CRN) scoring system: NAS (NAFLD Activity Score) = steatosis (0–3) + lobular inflammation (0–3) + ballooning (0–2); NAS ≥5 correlates with MASH. Fibrosis staged 0–4 (METAVIR-equivalent). Biopsy is indicated when: non-invasive tests are discordant; competing diagnoses need exclusion; before enrollment in clinical trials; or before initiating specific pharmacotherapy.

7. Treatment

Lifestyle Modification — Foundation of Treatment

• Weight loss: Most effective intervention; 5–7% body weight loss reduces hepatic steatosis; 7–10% improves MASH histology (NAS score reduction); ≥10% achieves fibrosis regression in 45% of patients (LEAN trial); ≥10–15% may achieve histological MASH resolution
• Dietary interventions: Mediterranean diet is best studied — reduces hepatic fat, ALT, and metabolic risk; reduce refined carbohydrates and fructose (high-fructose corn syrup); increase omega-3 rich foods (fatty fish, nuts); avoid ultra-processed foods and sugar-sweetened beverages
• Physical activity: 150–300 minutes/week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming); resistance training additionally improves hepatic fat independent of weight loss; exercise reduces liver fat by 20–30% in RCTs
• Alcohol abstinence: Even moderate alcohol consumption accelerates fibrosis in MASH; complete abstinence recommended for patients with advanced fibrosis
• Coffee consumption: Observational data suggest ≥2 cups/day of filtered coffee is associated with reduced fibrosis progression; do not routinely advise initiation but do not discourage existing consumption

Pharmacotherapy — Approved and Guideline-Recommended

• Resmetirom (Rezdiffra): FDA-approved March 2024 for adults with MASH and moderate-to-advanced liver fibrosis (F2/F3); thyroid hormone receptor-β (THRβ) agonist — reduces hepatic DNL, improves mitochondrial fat oxidation, reduces liver fat and inflammation; MAESTRO-NASH trial: MASH resolution without fibrosis worsening in 26% (80 mg) and 30% (100 mg) vs. 10% placebo; fibrosis improvement by ≥1 stage in 24–26% vs. 14% placebo; dose: 80 mg/day (BMI <35) or 100 mg/day (BMI ≥35)
• Vitamin E (alpha-tocopherol 800 IU/day): Recommended by AASLD for non-diabetic adults with biopsy-proven NASH (PIVENS trial); reduces NAS and improves MASH resolution; not recommended for diabetic patients, men with prostate cancer risk, or as long-term therapy without monitoring
• Pioglitazone (thiazolidinedione): Recommended for MASH with or without T2DM (AASLD 2023 update); improves steatosis, inflammation, and fibrosis via PPARγ agonism; side effects: weight gain, fluid retention, bone loss; dose 30–45 mg/day

GLP-1 Receptor Agonists

• Semaglutide 2.4 mg/week (Wegovy): Phase 2 trial showed MASH resolution in 59% vs. 17% placebo; fibrosis improvement did not reach significance; ESSENCE trial (phase 3 with fibrosis endpoint) results expected 2025; currently used off-label for MASLD in patients with obesity/T2DM
• Liraglutide 1.8 mg/day (Victoza/Saxenda): Phase 2 LEAN trial showed NASH resolution in 39% vs. 9% placebo; approved for T2DM and obesity, used off-label for MASH
• Tirzepatide (dual GLP-1/GIP agonist): SYNERGY-NASH phase 3 trial with promising phase 2 data showing >70% MASH resolution at higher doses

SGLT2 Inhibitors

Empagliflozin and dapagliflozin reduce liver fat (MRI-PDFF), ALT, and AST; phase 3 fibrosis outcome data pending. Currently recommended for MASLD patients with T2DM for cardiovascular and renal protection.

Management of Metabolic Comorbidities

• Aggressive treatment of T2DM, hypertension, dyslipidemia, and obesity
• Statin therapy: safe in MASLD/MASH; may reduce HCC incidence; do not withhold due to elevated liver enzymes (ALT <3 times ULN is not a contraindication)
• Bariatric surgery: most effective intervention for severe obesity-associated MASH; Roux-en-Y gastric bypass and sleeve gastrectomy achieve MASH resolution in 80–90% and fibrosis regression in 65–70% (COURAGE trial); considered if BMI >40 or BMI >35 with significant comorbidities

Cirrhosis Management

Patients with MASH cirrhosis require: HCC surveillance (ultrasound ± AFP every 6 months); management of portal hypertension complications (see Cirrhosis article); evaluation for liver transplantation in decompensated disease (MELD-Na ≥15). Post-transplant MASH recurrence occurs in 15–30% but rarely affects graft survival if metabolic risk factors are controlled.

8. Complications

• Hepatocellular carcinoma (HCC): Annual incidence 2–4% in MASH cirrhosis; 0.3% in MASH without cirrhosis; increasing proportion of total HCC burden globally; often diagnosed at advanced stage due to insufficient surveillance in non-cirrhotic MASH
• Cirrhosis and liver failure: Occurs in 2–3% of MASH patients over 10 years (those with significant fibrosis at baseline); leading indication for liver transplantation
• Cardiovascular disease: Leading cause of mortality in MASLD (responsible for 40% of deaths); MASLD independently associates with atherosclerosis, myocardial infarction, and stroke beyond shared metabolic risk factors
• Type 2 diabetes: MASLD independently predicts T2DM development (2-fold increased risk); bidirectional relationship
• Chronic kidney disease: MASLD associated with 1.5–2 fold increased CKD risk; shared metabolic risk factors and possibly hepatokine-mediated renal effects
• Extrahepatic cancers: MASLD/obesity associated with increased risk of colorectal, breast, and esophageal cancers; age-appropriate cancer surveillance recommended

9. Prognosis

Prognosis in MASLD is strongly determined by the stage of fibrosis at presentation. Liver-related mortality is negligible in MASL (simple steatosis) and MASH without fibrosis but increases sharply with advancing fibrosis:

• F0/F1 (no/minimal fibrosis): Liver-related mortality <0.5% over 10 years; all-cause mortality driven by cardiovascular disease
• F2 (moderate fibrosis): Liver-related mortality 1–2% per year
• F3 (bridging fibrosis): Liver-related mortality 3–5% per year; 5-year transplant-free survival ~85%
• F4 (cirrhosis): Annual liver-related mortality 5–10%; 5-year transplant-free survival 60–75% (compensated) declining to <30% after decompensation

The rate of fibrosis progression varies widely: median time from F0 to F1 approximately 7 years in MASLD overall but 3–4 years in MASH. Approximately 20–30% of MASH patients with F0 progress to F2+ within 5 years. Diabetes is the strongest predictor of rapid fibrosis progression. Fibrosis regression is possible with sustained treatment: 45% of patients achieving ≥10% weight loss show at least 1-stage fibrosis improvement.

10. Prevention

• Primary prevention: Public health initiatives promoting healthy diet (Mediterranean/DASH diet), physical activity, and obesity prevention; reduction of sugar-sweetened beverages and ultra-processed food consumption; sugar taxes shown to reduce intake in population studies
• Early identification: FIB-4 screening in primary care for all patients with T2DM or obesity; 2024 AASLD/EASL guidelines recommend FIB-4 as initial fibrosis assessment in all MASLD patients; enables early referral of high-risk patients to hepatology before progression to cirrhosis
• Metabolic syndrome management: Aggressive glycemic control (HbA1c <7%), weight management, treatment of dyslipidemia and hypertension
• HCC surveillance: All patients with MASH cirrhosis and selected patients with advanced fibrosis (F3) should undergo HCC surveillance
• Drug avoidance: Avoid hepatotoxic medications (amiodarone, methotrexate, tamoxifen) in patients with established MASLD when alternatives exist
• Bariatric surgery consideration: Most effective preventive strategy for progression in morbidly obese patients with MASH

11. Recent Research and Advances

• Resmetirom FDA approval (2024): First drug specifically approved for MASH with fibrosis; landmark MAESTRO-NASH trial results published in NEJM 2024; clinical availability is transforming MASH management
• Obeticholic acid (OCA, FXR agonist): REGENERATE trial phase 3 showed fibrosis improvement but did not meet primary endpoints for MASH resolution; EMA refused marketing authorization; FDA approval application active; pruritus and increased LDL are key adverse effects
• ESSENCE trial (semaglutide 2.4 mg): Phase 3 RCT with histological and clinical outcomes in MASH ongoing; phase 2 data (NEJM 2021) highly encouraging; expected to confirm fibrosis benefit with larger sample
• SYNERGY-NASH (tirzepatide phase 3): Phase 2 data (2023) showed 62% MASH resolution at highest dose; phase 3 endpoints include fibrosis regression
• ARO-HSD (RNAi targeting HSD17B13): Subcutaneous injection reducing HSD17B13 expression (loss-of-function variant protects against MASH progression); phase 2 data show significant ALT reduction and histological improvement; potential for genetic risk-guided precision therapy
• Lanifibranor (pan-PPAR agonist α/δ/γ): NATIVE trial showed significant improvement in MASH NAS and fibrosis; EMA review ongoing; broad metabolic effects across lipid, glucose, and inflammatory pathways
• MASLD nomenclature change (2023): Multi-society consensus statement replacing NAFLD with MASLD acknowledges positive metabolic criteria rather than exclusion diagnosis; MASH replaces NASH; MetALD category introduced for those with both metabolic dysfunction and moderate alcohol use
• Gut microbiome therapeutics: Fecal microbiota transplantation (FMT) and prebiotics under investigation; microbiome signatures associated with MASH fibrosis severity; Akkermansia muciniphila supplementation showed metabolic benefits in phase 2 trials

12. References

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. doi:10.1097/HEP.0000000000000520
2. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). New England Journal of Medicine. 2024;390(6):497–509. doi:10.1056/NEJMoa2309000
3. Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways. Current Hepatology Reports. 2018;17(4):350–360. doi:10.1007/s11901-018-0427-5
4. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014. doi:10.1053/j.gastro.2019.11.312
5. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine. 2021;384(12):1113–1124. doi:10.1056/NEJMoa2028395
6. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the AASLD. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
7. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–1625. doi:10.1053/j.gastro.2020.01.043
8. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). New England Journal of Medicine. 2010;362(18):1675–1685. doi:10.1056/NEJMoa0907929
9. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics. 2008;40(12):1461–1465. doi:10.1038/ng.257
10. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
11. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis (COURAGE trial). Gastroenterology. 2020;159(4):1290–1301. doi:10.1053/j.gastro.2020.06.006
12. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism, and cardiovascular risk in nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904. doi:10.1007/s00125-011-2446-4
13. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
14. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378. doi:10.1053/j.gastro.2015.04.005
15. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9

Back to Table of Contents